These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis. Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418 [TBL] [Abstract][Full Text] [Related]
46. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214 [TBL] [Abstract][Full Text] [Related]
47. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454 [TBL] [Abstract][Full Text] [Related]
48. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose. Cook SD J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397 [TBL] [Abstract][Full Text] [Related]
49. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B; Tremlett H Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
50. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165 [TBL] [Abstract][Full Text] [Related]
51. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis]. Cendrowski W Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611 [TBL] [Abstract][Full Text] [Related]
52. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Flechter S; Vardi J; Finkelstein Y; Pollak L Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394 [TBL] [Abstract][Full Text] [Related]
53. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
54. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Goodin DS Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209 [TBL] [Abstract][Full Text] [Related]
55. Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project. Bonavita S; Dinacci D; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Bresciamorra V; Orefice G; Paciello M; Coniglio G; Di Costanzo A; Valentino P; Patti F; Salemi G; Simone I; Tedeschi G Neurol Sci; 2006 Sep; 27 Suppl 5():S365-8. PubMed ID: 16998722 [TBL] [Abstract][Full Text] [Related]
56. Defining interferon beta response status in multiple sclerosis patients. Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896 [TBL] [Abstract][Full Text] [Related]
57. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis. Murray TJ Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068 [TBL] [Abstract][Full Text] [Related]
58. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877 [TBL] [Abstract][Full Text] [Related]
59. [Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy]. Samson M; Audia S; Duchêne C; Perinet I; Bielefeld P; Besancenot JF Rev Med Interne; 2009 Sep; 30(9):816-9. PubMed ID: 19201069 [TBL] [Abstract][Full Text] [Related]
60. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Chiu AW; Richert N; Ehrmantraut M; Ohayon J; Gupta S; Bomboi G; Gaindh D; Cantor FK; Frank JA; McFarland HF; Bagnato F Arch Neurol; 2009 Jan; 66(1):39-43. PubMed ID: 19001157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]